The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
Cybin's bought deal financing has been upsized to CAD$30 million.
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
